Multiple myeloma (kahlers disease) – pipeline review, h2 2012
Upcoming SlideShare
Loading in...5
×
 

Multiple myeloma (kahlers disease) – pipeline review, h2 2012

on

  • 120 views

2012 | Aarkstore.com || Multiple myeloma (kahlers disease) – pipeline review, h2 2012

2012 | Aarkstore.com || Multiple myeloma (kahlers disease) – pipeline review, h2 2012

Statistics

Views

Total Views
120
Views on SlideShare
120
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Multiple myeloma (kahlers disease) – pipeline review, h2 2012 Multiple myeloma (kahlers disease) – pipeline review, h2 2012 Document Transcript

  • Aarkstore.com announces, The Latest market research report is available inits vast collection:Multiple Myeloma (Kahlers Disease) – Pipeline Review, H22012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Multiple Myeloma (Kahlers Disease) - Pipeline Review, H22012, provides an overview of the indication’s therapeutic pipeline. This reportprovides information on the therapeutic development for Multiple Myeloma(Kahlers Disease), complete with latest updates, and special features on late-stageand discontinued projects. It also reviews key players involved in the therapeuticdevelopment for Multiple Myeloma (Kahlers Disease). Multiple Myeloma (KahlersDisease) - Pipeline Review, Half Year is built using data and information sourcedfrom Global Markets Direct’s proprietary databases, Company/University websites,SEC filings, investor presentations and featured press releases fromcompany/university sites and industry-specific third party sources, put together byGlobal Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Multiple Myeloma (KahlersDisease).
  • - A review of the Multiple Myeloma (Kahlers Disease) products under developmentby companies and universities/research institutes based on information derivedfrom company and industry-specific sources.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Multiple Myeloma (Kahlers Disease).- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 8List of Figures 13Introduction 14Global Markets Direct Report Coverage 14Multiple Myeloma (Kahlers Disease) Overview 15Therapeutics Development 16An Overview of Pipeline Products for Multiple Myeloma (Kahlers Disease) 16Multiple Myeloma (Kahlers Disease) Therapeutics under Development byCompanies 18Multiple Myeloma (Kahlers Disease) Therapeutics under Investigation byUniversities/Institutes 27Late Stage Products 39Comparative Analysis 39Mid Clinical Stage Products 40Comparative Analysis 40Early Clinical Stage Products 41Comparative Analysis 41Discovery and Pre-Clinical Stage Products 42Comparative Analysis 42Multiple Myeloma (Kahlers Disease) Therapeutics – Products under Developmentby Companies 43Multiple Myeloma (Kahlers Disease) Therapeutics – Products under Investigation byUniversities/Institutes 56
  • Companies Involved in Multiple Myeloma (Kahlers Disease) TherapeuticsDevelopment 87Bristol-Myers Squibb Company 87Johnson & Johnson 88Kyowa Hakko Kirin Co., Ltd. 89Abbott Laboratories 90Amgen Inc. 91Eli Lilly and Company 92Viralytics Ltd. 93GlaxoSmithKline plc 94Seattle Genetics, Inc. 95Genentech, Inc. 96List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Multiple Myeloma (Kahlers Disease) – Pipeline Review, H2 2012Respiratory Depression – Pipeline Review, H2 2012Metastatic Cancer – Pipeline Review, H2 2012Viral Infections – Pipeline Review, H2 2012
  • Central Nervous System (CNS) Cancer – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanya
  • Phone:08149852585Email: enquiry@aarkstore.com